Neurocognición, factores sensoriales y de calidad de sueño en situaciones extremas de peso corporal y trastornos alimentares afines

Los problemas relacionados con el peso y la alimentación, incluyendo los trastornos de la conducta alimentaria (TCA) y la obesidad, se asocian con una amplia gama de trastornos físicos y mentales. La tasa de obesidad entre adultos y adolescentes se ha duplicado en los últimos 20 años, mientras que, paralelamente, también se ha registrado un aumento en la prevalencia de TCA. A pesar de que la obesidad y los TCA se tratan y estudian como patologías diferentes, diversos estudios han identificado factores de riesgo y protectores que son comunes entre ambas afectaciones. Sin embargo, pocos son los estudios que analizan conjuntamente factores neuropsicológicos, biológicos y ambientales, de manera a determinar las interacciones existentes entre estos aspectos.Objetivos:1) Explorar las diferencias clínicas (conducta alimentaria, actividad y sueño y personalidad), neuropsicológicas (funciones ejecutivas y de atención) y del sistema olfativo-sensorial entre los dos diferentes subtipos de TCA y la obesidad, al ser comparado entre los grupos; 2) Explorar la asociación entre funcionamiento neuropsicológico y características clínicas (conducta alimentaria y perfil de personalidad), IMC y sistema olfativo-sensorial entre los distintos grupos. Método: Estudio transversal de casos y controles. La muestra será dividida en 4 grupos: 2 de casos (30 bajo peso con TCA y 30 Obesas con TCA), formados por pacientes admitidos, tratados en la Unidad de Trastornos Alimentarios y diagnosticados según el DSM-IV; y 2 de controles (30 bajo peso sin TCA y 30 Obesas sin TCA). CRITERIOS DE INCLUSION: Ser mujer, tener entre 18-45 años, Cumplir criterios diagnósticos DSM-IV (en caso TCA). Instrumentos: 1)Neuropsicologicos: TCI-R, WCST, SCWT; 2)Antropométricos: TANITA MC-180 Multifrecuencia; 3)Olfato-sensoriales: SSOT, Taste Strips; 4)Actividad: ACTIWATCH 7; 5)Calidad del sueño: PSQI ,Escala EPWORTH.Variables socio-demográficas también serán recogidas durante la entrevista clínica. Todos los instrumentos serán aplicados en la misma unidad en una única entrevista exceptuando el ACTIWATCH que los sujetos deberán llevar durante 6 días.

El suport familiar en la malaltia mental: influència del suport familiar en el control de la malaltia en una persona que pateix un transtorn mental server

Aquest treball té com a objectiu principal conèixer si hi ha millora en el control de la malaltia d’una persona que pateix un trastorn mental sever quan disposa d’un suport adequat de la família. Els objectius específics marcats són, avaluar la càrrega familiar que suposa tenir la responsabilitat de cuidar un familiar amb malaltia mental, conèixer les actituds dels familiars de persones que pateixen una malaltia mental, involucrar a la família dins de la teràpia del familiar amb malaltia mental severa, i aconseguir un grau de cooperació i comunicació favorable de la família al pacient. Es tracta d’un estudi d’investigació quantitatiu, transversal i de tipus analític, el qual la mostra de la població estudiada estarà composta de 100 pacients entre 20 i 30 anys amb diagnòstic de trastorn mental sever segons el DSM-IV, atesos durant l’últim any en el Centre de Salut Mental d’Adults de Vic i els seus cuidadors principals o persones més properes. Es realitzarà recollida de dades a través de la revisió de les històries clíniques, informació facilitada pel terapeuta que tracta al pacient i entrevistes als familiars cuidadors o persona més propera i als mateixos pacients. Aquesta entrevista la faran professionals entrenats i competents. Amb tot això s’establirà una correlació entre les variables d’estrès, suport als familiars i el desenvolupament dels rols, i s’agruparan les variables de manera que quedin estructurades en subgrups.

A comparison of the dental status and treatment needs of older adults with and without chronic mental illness in Sevilla, Spain

Objectives: To study the dental status and treatment needs of institutionalized older adults with chronic mental illness compared to a non-psychiatric control sample. Study Design: The sample size was 100, in which 50 were psychogeriatric patients (study group; SG) classified according to DSM-IV, with a mean age of 69.6 ± 6.7 years, and 50 non-psychiatric patients (control group; CG), with a mean age of 68.3 ± 6.9 years. Clinical oral health examinations were conducted and caries were recorded clinically using the Decayed, Missing and Filled Teeth Index (DMFT). Results were analyzed statistically using the Student"s t-test or analysis of variance. Results: Caries prevalence was 58% and 62% in SG and CG, respectively. DMFT index was 28.3 ± 6.6 in SG and 21.4 ± 6.07 in CG (p < 0.01). Mean number of decayed teeth was higher in SG (3.1) compared to CG (1.8) (p=0.047). Mean number of missing teeth were 25.2 and 16.4 in SG and CG respectively (p<0.05). DMFT scores were higher in SG in all the age groups (p < 0.01). Mean number of teeth per person needing treatment was 3.4 in SG and 1.9 in CG (p= 0.037). The need for restorative dental care was significantly lower in the SG (0.8 teeth per person) than in the CG (1.7 teeth per person) (p = 0.043). Conclusions: Institutionalized psychiatric patients have significantly worse dental status and more dental treatment needs than non-psychiatric patients.

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.

Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic reviews or meta-analyses to evaluate the efficacy of modern atypical antipsychotics in bipolar depression. We systematically reviewed published or registered randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I and/or II depressive patients (DSM-IV criteria). Efficacy outcomes were assessed based on changes in the Montgomery-Asberg Depression Rating Scale (MADRS) during an 8-wk period. Data were combined through meta-analysis using risk ratio as an effect size with a 95% confidence interval (95% CI) and with a level of statistical significance of 5% (p<0.05). We identified five RCTs; four involved antipsychotic monotherapy and one addressed both monotherapy and combination with an antidepressant. The two quetiapine trials analysed the safety and efficacy of two doses: 300 and 600 mg/d. The only olanzapine trial assessed olanzapine monotherapy within a range of 5-20 mg/d and olanzapine-fluoxetine combination within a range of 5-20 mg/d and 6-12 mg/d, respectively. The two aripiprazole placebo-controlled trials assessed doses of 5-30 mg/d. Quetiapine and olanzapine trials (3/5, 60%) demonstrated superiority over placebo (p<0.001). Only 2/5 (40%) (both aripiprazole trials) failed in the primary efficacy measure after the first 6 wk. Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards. Rapid onset of action seems to be a common feature of atypical antipsychotics in bipolar depression. Comment in The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface controlEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis--results to be interpreted with caution.

Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study.

BACKGROUND: Previous cross-sectional studies report that cognitive impairment is associated with poor psychosocial functioning in euthymic bipolar patients. There is a lack of long-term studies to determine the course of cognitive impairment and its impact on functional outcome. Method A total of 54 subjects were assessed at baseline and 6 years later; 28 had DSM-IV TR bipolar I or II disorder (recruited, at baseline, from a Lithium Clinic Program) and 26 were healthy matched controls. They were all assessed with a cognitive battery tapping into the main cognitive domains (executive function, attention, processing speed, verbal memory and visual memory) twice over a 6-year follow-up period. All patients were euthymic (Hamilton Rating Scale for Depression score lower than 8 and Young mania rating scale score lower than 6) for at least 3 months before both evaluations. At the end of follow-up, psychosocial functioning was also evaluated by means of the Functioning Assessment Short Test. RESULTS: Repeated-measures multivariate analysis of covariance showed that there were main effects of group in the executive domain, in the inhibition domain, in the processing speed domain, and in the verbal memory domain (p<0.04). Among the clinical factors, only longer illness duration was significantly related to slow processing (p=0.01), whereas strong relationships were observed between impoverished cognition along time and poorer psychosocial functioning (p<0.05). CONCLUSIONS: Executive functioning, inhibition, processing speed and verbal memory were impaired in euthymic bipolar out-patients. Although cognitive deficits remained stable on average throughout the follow-up, they had enduring negative effects on psychosocial adaptation of patients.

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.

Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic reviews or meta-analyses to evaluate the efficacy of modern atypical antipsychotics in bipolar depression. We systematically reviewed published or registered randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I and/or II depressive patients (DSM-IV criteria). Efficacy outcomes were assessed based on changes in the Montgomery-Asberg Depression Rating Scale (MADRS) during an 8-wk period. Data were combined through meta-analysis using risk ratio as an effect size with a 95% confidence interval (95% CI) and with a level of statistical significance of 5% (p<0.05). We identified five RCTs; four involved antipsychotic monotherapy and one addressed both monotherapy and combination with an antidepressant. The two quetiapine trials analysed the safety and efficacy of two doses: 300 and 600 mg/d. The only olanzapine trial assessed olanzapine monotherapy within a range of 5-20 mg/d and olanzapine-fluoxetine combination within a range of 5-20 mg/d and 6-12 mg/d, respectively. The two aripiprazole placebo-controlled trials assessed doses of 5-30 mg/d. Quetiapine and olanzapine trials (3/5, 60%) demonstrated superiority over placebo (p<0.001). Only 2/5 (40%) (both aripiprazole trials) failed in the primary efficacy measure after the first 6 wk. Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards. Rapid onset of action seems to be a common feature of atypical antipsychotics in bipolar depression. Comment in The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface controlEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis--results to be interpreted with caution.

Two-year follow-op of cognitive functions in Schizophrenia spectrum disorders of adolescent patients treated with electroconvulsive therapy

Objective: The aim of the current study was to investigate the long-term cognitive effects of electroconvulsive therapy (ECT) in a sample of adolescent patients in whom schizophrenia spectrum disorders were diagnosed. Methods: The sample was composed of nine adolescent subjects in whom schizophrenia or schizoaffective disorder was diagnosed according to DSM-IV-TR criteria on whom ECT was conducted (ECT group) and nine adolescent subjects matched by age, socioeconomic status, and diagnostic and Positive and Negative Syndrome Scale (PANSS) total score at baseline on whom ECT was not conducted (NECT group). Clinical and neuropsychological assessments were carried out at baseline before ECT treatment and at 2-year follow-up. Results: Significant differences were found between groups in the number of unsuccessful medication trials. No statistically significant differences were found between the ECT group and theNECT group in either severity as assessed by the PANSS, or in any cognitive variables at baseline.At follow-up, both groups showed significant improvement in clinical variables (subscales of positive, general, and total scores of PANSS and Clinical Global Impressions-Improvement). In the cognitive assessment at follow-up, significant improvement was found in both groups in the semantic category of verbal fluency task and digits forward. However, no significant differences were found between groups in any clinical or cognitive variable at follow-up. Repeated measures analysis found no significant interaction of time · group in any clinical or neuropsychological measures. Conclusions: The current study showed no significant differences in change over time in clinical or neuropsychological variables between the ECT group and the NECT group at 2-year follow-up. Thus, ECT did not show any negative influence on long-term neuropsychological variables in our sample.

Mood and anxiety disorders across the adult lifespan: a European perspective

BACKGROUND: The World Mental Health Survey Initiative (WMHSI) has advanced our understanding of mental disorders by providing data suitable for analysis across many countries. However, these data have not yet been fully explored from a cross-national lifespan perspective. In particular, there is a shortage of research on the relationship between mood and anxiety disorders and age across countries. In this study we used multigroup methods to model the distribution of 12-month DSM-IV/CIDI mood and anxiety disorders across the adult lifespan in relation to determinants of mental health in 10 European Union (EU) countries. METHOD: Logistic regression was used to model the odds of any mood or any anxiety disorder as a function of age, gender, marital status, urbanicity and employment using a multigroup approach (n = 35500). This allowed for the testing of specific lifespan hypotheses across participating countries. RESULTS: No simple geographical pattern exists with which to describe the relationship between 12-month prevalence of mood and anxiety disorders and age. Of the adults sampled, very few aged ≥ 80 years met DSM-IV diagnostic criteria for these disorders. The associations between these disorders and key sociodemographic variables were relatively homogeneous across countries after adjusting for age. CONCLUSIONS: Further research is required to confirm that there are indeed stages in the lifespan where the reported prevalence of mental disorders is low, such as among younger adults in the East and older adults in the West. This project illustrates the difficulties in conducting research among different age groups simultaneously.

The factorial structure of the 41-item version of the Screen for Child Anxiety Related Emotional Disorders (SCARED) in a Spanish population of 8 to 12 years-old

On this instrumental study we intend to analyse the factorial structure of the Screen for Child Anxiety Related Emotional Disorders (SCARED) in a Spanish sample using exploratory and confirmatory factorial analysis. As a second objective we intend to develop a short form of it for rapid screening and, finally, to analyze the reliabilities of both questionnaires. The SCARED was administered to a community sample of 1,508 children aged between 8 and 12 years. The sample was randomly split using half for the exploratory analysis and the other half for the confirmatory study. Furthermore a reduced version of the SCARED was developed using the SchmidLeiman procedure. Exploratory Factor Analysis yielded a four factor structure comprised of Somatic/panic, Generalized anxiety, Separation anxiety and Social phobia factors This structure was confirmed using Confirmatory Factor Analysis. The four factors, the full scale and the short scale showed good reliabilities. The results obtained seem to indicate that the Spanish version of the SCARED has good internal consistency, and along with other recent results, has a structure of four related factors that replicates the dimensions proposed for anxiety disorders by the DSM-IV-TR

Embedding theorems of function classes, IV

Vegeu el resum a l'inici del document del fitxer adjunt

On hyperbolic once-punctured-torus bundles IV: automata for lightning curves

"Vegeu el resum a l'inici del document del fitxer adjunt."

Impacte de les mutacions del gen KRAS en pacients afectes de carcinoma no microcític de pulmó estadi IV i la seva relació amb altres biomarcadors

Hem analitzat la mutació KRAS i els seus subtipus en mostres tumorals de 114 pacients diagnosticats d’un carcinoma de pulmó estadi IV. Un 21,9% dels pacients presentaren la mutació de KRAS. Dels seus subtipus, la més freqüent va ser G12C (44%). Dels pacients tractats amb quimioteràpia s’obtingueren un 4,8% de respostes completes i un 47,6% presentaren progressió de la malaltia. S’observà una tendència significativa a menor temps fins a la progressió i major supervivència global acord amb el performance status i els nivells de RAP 80.Els pacients KRAS-G12C presentaren una tendència no significativa a major supervivència global respecte els altres.

La ineficàcia de les disposicions testamentàries en el llibre IV del Codi civil de Catalunya

El llibre IV reconeix sols la possibilitat de nul•litat. La crisi convivencial posterior al testament comporta la ineficàcia. La manca originària o sobrevinguda d’hereu té conseqüències diferenciades. L’hereu contractual i l’intestat poden detreure la falcídia.